Core Biopsy Needles MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ApplicationBy Clinical IndicationBy Imaging GuidanceBy Distribution Channel

Core needle biopsy devices are handheld or gun-style instruments that extract a solid cylindrical tissue sample from a suspicious lesion for histopathological diagnosis, most commonly used to confirm or rule out breast, prostate and other solid-organ cancers. The category spans manual, semi-automated (spring-loaded) and full-automated designs used under ultrasound, stereotactic, MRI or CT imaging guidance. Buyers are hospital radiology and pathology departments, diagnostic imaging centers and outpatient clinics that perform image-guided tissue sampling.

Growth of 6.8% a year carries the global core biopsy needles market from USD 950 million in 2025 to USD 1718 million in 2034. The full series behind that rate covers USD 705 million in 2020, USD 900 million in 2024, USD 1015 million in 2026 and USD 1320 million in 2030, with 2025 as the base year.

Composition changes more than the total does. Full-automated core needle biopsy device, at 9.33%, outgrows Manual core needle biopsy device at 3.4%, and its share moves from 42% to 52%. Semi-automated core needle biopsy device stays the largest line throughout, at USD 475 million in 2025 and USD 721.5 million in 2034. Share moves toward Full-automated core needle biopsy device and away from Semi-automated core needle biopsy device and Manual core needle biopsy device, though no line shrinks in revenue terms.

The application split puts Hospitals first, at USD 570 million and 60% of revenue in 2025, rising to USD 996.4 million and 58% in 2034. Clinics grows faster at 7.87% against 6.4%, moving from 32% of revenue to 35% by 2034. It cuts the same total as the type axis from a different commercial angle, so revenue does not add across the two.

USD 361 million of 2025 revenue is generated in North America, 38% of the global total and the largest regional share; it reaches USD 601.3 million by 2034. Europe is next at 26% and USD 247 million, and Middle East and Africa last at 4%. Because Asia Pacific, Latin America and Middle East and Africa take share, the revenue added by 2034 concentrates instead of spreading across all five regions.

Behind these figures sit five regions, three type lines and five segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is arrived at by triangulating published aggregates against category proxies, not by an independent count, and the same applies to the segment, regional and country breakdowns drawn from it.

• A forecast-period rate of 6.8% takes the market from USD 950 million in 2025 to USD 1718 million in 2034, against 6.15% recorded over the 2020-2025 historical period.
• The largest line by type is Semi-automated core needle biopsy device, worth USD 475 million and 50% of revenue in 2025, rising to USD 721.5 million and 42% by 2034.
• At 9.33%, Full-automated core needle biopsy device grows faster than any other type line, moving from USD 399 million and 42% of revenue in 2025 to USD 893.4 million and 52% in 2034.
• Against a base case of USD 1718 million in 2034, the study also reports a bear case at USD 1625.2 million and a bull case at USD 1795.3 million, with the assumptions behind each set out separately.
• The largest region is North America, generating USD 361 million in 2025 (38% of the global total) and USD 601.3 million by 2034, ahead of Europe at 26%.
• Within North America, the United States is the worked country example, at USD 306.9 million in 2025; 85% of regional revenue in the base year, and USD 505.1 million by 2034.
• The study covers 2020 through 2034 with 2025 as the base year, reporting five regions and five segmentation axes separately, with revenue, share and a growth rate for every line in each year.

Read across the forecast period, the global core biopsy needles market shows movement in three places: type composition, regional weight, and the 6.8% rate applied to the whole.

The direction of the market is not in question in any of the three. Each line and each region grows in revenue terms; what separates them is which takes the larger part of the growth.

Composition shifts on the type axis. 9.33% against 3.4%: that gap, between Full-automated core needle biopsy device and Manual core needle biopsy device, is the largest on the type axis. By 2034 the two sit at 52% and 6% of revenue, against 42% and 8% in 2025. In absolute terms Full-automated core needle biopsy device rises from USD 399 million to USD 893.4 million, while Manual core needle biopsy device rises from USD 76 million to USD 103.1 million. Both grow; the gap is wide enough to reshape the mix inside a single forecast window.

Asia Pacific, Latin America and Middle East and Africa gain regional share. Asia Pacific moves from 26% of revenue in 2025 to 30% in 2034, worth USD 247 million rising to USD 515.4 million; Latin America moves from 6% of revenue in 2025 to 6.5% in 2034, worth USD 57 million rising to USD 111.7 million; Middle East and Africa moves from 4% of revenue in 2025 to 4.5% in 2034, worth USD 38 million rising to USD 77.3 million. Against that, North America at 38% moving to 35%, Europe at 26% moving to 24%, a fall in share, not in revenue. Growth is therefore not something a participant inherits from the market; it depends on which regions its revenue is weighted toward.

Fifteen years without a discontinuity. The market moves through USD 705 million in 2020, USD 900 million in 2024, USD 950 million in 2025, USD 1015 million in 2026, USD 1320 million in 2030 and USD 1718 million in 2034. There is no discontinuity to time, and 6.8% forecast growth against 6.15% historical means the trend continues and does not turn. That moves the planning question away from timing a turn and onto the type and regional mixes, where the actual movement is.

The fastest line decides the blended rate

The 6.8% forecast rate rests on three things that can be measured separately: the size of the existing base, the mix shift on the type axis, and where regional growth is concentrated.

The bear case and what drives it

Where the forecast could be beaten

The total depends on a single line

In North America, 38% of global revenue puts 2025 at USD 361 million rising to USD 601.3 million in 2034. By revenue it sits first across the study, and the ranking does not change between 2025 and 2034.

Its share moves to 35% by 2034, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

The type mix reported at global level applies here, with Semi-automated core needle biopsy device the largest line at 50% of 2025 revenue and Full-automated core needle biopsy device the fastest-growing at 9.33%. Revenue for North America is broken out by every segmentation axis and by country in the full report.

The United States is the largest market within North America, generating USD 306.9 million in 2025 and projected to reach USD 505.1 million by 2034. Carrying 85% of the region in the base year, it sets North America's direction instead of merely contributing to it. Regional revenue of USD 361 million in 2025 and USD 601.3 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Demand in the United States follows the type mix reported at global level: Semi-automated core needle biopsy device is the largest line at 50% of 2025 revenue, moving to 42% by 2034, while Full-automated core needle biopsy device grows fastest at 9.33% and takes its share from 42% to 52%. With 85% of North America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The United States carries its own type breakdown in the full report.

Core biopsy needles fall under the Food and Drug Administration's medical device framework, regulated by the Center for Devices and Radiological Health. As invasive instruments intended to sample tissue, they are generally classified in the moderate-risk tier and cleared through the premarket notification pathway by demonstrating substantial equivalence to an already-marketed device. Manufacturers must register their facilities, list their devices, and operate under the Quality System Regulation covering design controls, production, and complaint handling. Labelling must state intended use, sterility status, and any single-use designation, and must comply with the agency's general device labelling requirements. Post-market obligations include adverse event reporting through the agency's vigilance system and participation in the unique device identification program so that individual units can be traced from manufacture through clinical use.

Competition in the United States runs between the suppliers this study tracks: BD, Hologic, Inc., Devicor Medical Products, Inc., ARGON MEDICAL., SOMATEX Medical Technologies GmbH, INVIVO THERAPEUTICS, MDL SRL., STERYLAB S.r.l., UROMED Kurt Drews KG, BPB medica, Koninklijke Philips N.V., Medtronic, GENERAL ELECTRIC COMPANY, Leica Biosystems Nussloch GmbH, ZAMAR CARE., Stryker, Messe D&uuml, sseldorf GmbH, Kompass, COMPASS International Innovations, Inc., HAKKO CO. and LTD. and Cardinal Health. Two different problems sit on the same axis: holding Semi-automated core needle biopsy device at 50% of 2025 revenue, and taking Full-automated core needle biopsy device while it grows at 9.33%. The full report covers country-level positioning and shares company by company; this summary does not.

Canada is sized at USD 54.1 million in 2025, rising to USD 96.2 million by 2034; 5.7% of global revenue and 15% of North America. It is reported separately from the United States across every segmentation axis in the full report.

In Europe, 26% of global revenue puts 2025 at USD 247 million with USD 412.3 million projected for 2034. It is a leading region on this axis, second by revenue throughout the period.

Its share moves to 24% by 2034, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

The type mix reported at global level applies here, with Semi-automated core needle biopsy device the largest line at 50% of 2025 revenue and Full-automated core needle biopsy device the fastest-growing at 9.33%. Revenue for Europe is broken out by every segmentation axis and by country in the full report.

The largest single market in Europe is Germany, at USD 69.2 million in 2025 and USD 111.3 million in 2034. Its 28% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. The region itself runs USD 247 million to USD 412.3 million over the same period, and this is the market carrying the country-level detail in the full report.

Germany buys along the same lines as the market globally; Semi-automated core needle biopsy device first at 50% of 2025 revenue and 42% in 2034, Full-automated core needle biopsy device fastest at 9.33% on a share moving from 42% to 52%. Its 28% weight in Europe means those movements carry straight into the regional totals. The full report reports Germany by type separately.

As an European Union member state, Germany applies the EU Medical Device Regulation to core biopsy needles, administered nationally through the Federal Institute for Drugs and Medical Devices. A device of this kind requires conformity assessment by a notified body before it can carry the CE mark, with the manufacturer holding technical documentation that demonstrates safety, biocompatibility, and clinical performance. Sterile devices must meet the harmonised standards governing sterilisation validation, and labelling must follow the regulation's essential requirements, including intended purpose, batch traceability, and symbols recognised across the bloc. Manufacturers or their authorised representatives register the device in the European database on medical devices, and any serious incident must be reported to the competent authority under the regulation's vigilance obligations, keeping the product under continued surveillance after placement on the market.

BD, Hologic, Inc., Devicor Medical Products, Inc., ARGON MEDICAL., SOMATEX Medical Technologies GmbH, INVIVO THERAPEUTICS, MDL SRL., STERYLAB S.r.l., UROMED Kurt Drews KG, BPB medica, Koninklijke Philips N.V., Medtronic, GENERAL ELECTRIC COMPANY, Leica Biosystems Nussloch GmbH, ZAMAR CARE., Stryker, Messe D&uuml, sseldorf GmbH, Kompass, COMPASS International Innovations, Inc., HAKKO CO. and LTD. and Cardinal Health are the suppliers covered in Germany. Two different problems sit on the same axis: holding Semi-automated core needle biopsy device at 50% of 2025 revenue, and taking Full-automated core needle biopsy device while it grows at 9.33%. That makes Europe a 26% share of 2025 global revenue, USD 247 million rising to USD 412.3 million, for any supplier deciding where to concentrate.

5.7% of global revenue is generated in the United Kingdom; USD 54.3 million in 2025, reaching USD 90.7 million in 2034, and 22% of Europe.

France is sized at USD 44.5 million in 2025, rising to USD 74.2 million by 2034; 4.7% of global revenue and 18% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

26% of the global core biopsy needles market sits in Asia Pacific in 2025, worth USD 247 million rising to USD 515.4 million in 2034. It is a leading region on this axis, third by revenue throughout the period.

Share climbs to 30% by 2034, on growth above the market's own 6.8%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

Semi-automated core needle biopsy device leads here as it does globally, at 50% of 2025 revenue, and Full-automated core needle biopsy device again grows fastest at 9.33%. Revenue for Asia Pacific is broken out by every segmentation axis and by country in the full report.

35% of Asia Pacific's base-year revenue comes from China; USD 86.5 million, rising to USD 175.2 million by 2034. 35% of the region in the base year makes it the largest market here without making it the region. Regional revenue of USD 247 million in 2025 and USD 515.4 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Demand in China follows the type mix reported at global level: Semi-automated core needle biopsy device is the largest line at 50% of 2025 revenue, moving to 42% by 2034, while Full-automated core needle biopsy device grows fastest at 9.33% and takes its share from 42% to 52%. Its 35% weight in Asia Pacific means those movements carry straight into the regional totals. China carries its own type breakdown in the full report.

Core biopsy needles are regulated by the National Medical Products Administration, which classifies invasive tissue-sampling instruments according to the degree of risk they pose to the patient. A device in this category typically requires registration approval prior to marketing, supported by technical documentation, clinical evaluation, and evidence of manufacturing quality drawn from the national good manufacturing practice framework for medical devices. Imported products are reviewed alongside domestically produced ones, though foreign manufacturers generally work through a local agent who holds registration responsibilities within the country. Labelling and instructions for use must appear in Chinese and identify sterility, single-use status, and manufacturer details. Once approved, the product is subject to post-market surveillance and adverse event reporting administered through the same authority, which can suspend or revoke registration where safety concerns arise.

The suppliers tracked in this study (BD, Hologic, Inc., Devicor Medical Products, Inc., ARGON MEDICAL., SOMATEX Medical Technologies GmbH, INVIVO THERAPEUTICS, MDL SRL., STERYLAB S.r.l., UROMED Kurt Drews KG, BPB medica, Koninklijke Philips N.V., Medtronic, GENERAL ELECTRIC COMPANY, Leica Biosystems Nussloch GmbH, ZAMAR CARE., Stryker, Messe D&uuml, sseldorf GmbH, Kompass, COMPASS International Innovations, Inc., HAKKO CO. and LTD. and Cardinal Health) compete in China across the type lines above. The commercially relevant division is 50% of 2025 revenue in Semi-automated core needle biopsy device, where the volume is, against 9.33% growth in Full-automated core needle biopsy device, where share moves. A supplier weighted toward Asia Pacific is competing over a base of USD 247 million in 2025 reaching USD 515.4 million by 2034, 26% of global revenue at the start of that period.

6.5% of global revenue is generated in Japan; USD 61.8 million in 2025, reaching USD 113.4 million in 2034, and 25% of Asia Pacific.

3.9% of global revenue is generated in India; USD 37.1 million in 2025, reaching USD 103.1 million in 2034, and 15% of Asia Pacific.

6% of the global core biopsy needles market sits in Latin America in 2025, worth USD 57 million and reaches USD 111.7 million by 2034. It is a marginal region on this axis, fourth by revenue throughout the period.

6.5% of global revenue sits here by 2034, up from the 2025 level, on growth above the market's own 6.8%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

The type mix reported at global level applies here, with Semi-automated core needle biopsy device the largest line at 50% of 2025 revenue and Full-automated core needle biopsy device the fastest-growing at 9.33%. Per-axis and per-country detail for Latin America sits in the full report.

The largest single market in Latin America is Brazil, at USD 31.4 million in 2025 and USD 60.3 million in 2034. 55.1% of the region in the base year makes it the largest market here without making it the region. Regional revenue of USD 57 million in 2025 and USD 111.7 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Brazil buys along the same lines as the market globally; Semi-automated core needle biopsy device first at 50% of 2025 revenue and 42% in 2034, Full-automated core needle biopsy device fastest at 9.33% on a share moving from 42% to 52%. Its 55.1% weight in Latin America means those movements carry straight into the regional totals. Brazil carries its own type breakdown in the full report.

Brazil's health surveillance agency, Anvisa, oversees the registration and market authorisation of medical devices, including instruments used for percutaneous tissue biopsy. Depending on its classified risk level, a core biopsy needle generally proceeds through a registration process that examines technical and safety documentation rather than requiring a full local clinical trial, since equivalence to devices already cleared in reference markets can support the submission. Manufacturers must hold a valid Good Manufacturing Practice certification issued or recognised by the agency, and the device must carry labelling in Portuguese that states sterility, intended use, and traceability information consistent with national technical standards. Importers or local registration holders bear responsibility for post-market vigilance, reporting adverse events to the agency and maintaining the registration in good standing for the product to remain on the market.

In Brazil the field is BD, Hologic, Inc., Devicor Medical Products, Inc., ARGON MEDICAL., SOMATEX Medical Technologies GmbH, INVIVO THERAPEUTICS, MDL SRL., STERYLAB S.r.l., UROMED Kurt Drews KG, BPB medica, Koninklijke Philips N.V., Medtronic, GENERAL ELECTRIC COMPANY, Leica Biosystems Nussloch GmbH, ZAMAR CARE., Stryker, Messe D&uuml, sseldorf GmbH, Kompass, COMPASS International Innovations, Inc., HAKKO CO. and LTD. and Cardinal Health. The commercially relevant division is 50% of 2025 revenue in Semi-automated core needle biopsy device, where the volume is, against 9.33% growth in Full-automated core needle biopsy device, where share moves. A supplier weighted toward Latin America is competing over a base of USD 57 million in 2025 reaching USD 111.7 million by 2034, 6% of global revenue at the start of that period.

Within Latin America, Mexico accounts for 30% of regional revenue and 1.8% of the global total, worth USD 17.1 million in 2025 and USD 34.6 million by 2034.

USD 38 million of 2025 revenue is generated in Middle East and Africa, 4% of the global core biopsy needles market on the way to USD 77.3 million by 2034. It is a marginal region on this axis, fifth by revenue throughout the period.

Share climbs to 4.5% by 2034, at a pace above the 6.8% global rate, so this region warrants separate treatment and should not be scaled off the total.

Within the region the type split tracks the global one; 50% of 2025 revenue in Semi-automated core needle biopsy device, fastest growth of 9.33% in Full-automated core needle biopsy device. Per-axis and per-country detail for Middle East and Africa sits in the full report.

Saudi Arabia is the largest market within Middle East and Africa, generating USD 11.4 million in 2025 and projected to reach USD 24 million by 2034. It accounts for 30% of regional revenue in the base year, the largest single share without dominating the region outright. Regional revenue of USD 38 million in 2025 and USD 77.3 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Demand in Saudi Arabia follows the type mix reported at global level: Semi-automated core needle biopsy device is the largest line at 50% of 2025 revenue, moving to 42% by 2034, while Full-automated core needle biopsy device grows fastest at 9.33% and takes its share from 42% to 52%. Since 30% of Middle East and Africa's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Saudi Arabia carries its own type breakdown in the full report.

The Saudi Food and Drug Authority governs the marketing and use of medical devices in the kingdom, applying a risk-based classification system aligned with recognised international frameworks. A core biopsy needle, as an invasive sampling instrument, requires listing on the authority's national registry before distribution, supported by evidence of conformity to applicable safety and performance standards and, where relevant, marketing authorisation already granted by a reference regulator. Establishments importing or distributing the device must hold a valid medical device establishment licence, and labelling must appear in Arabic alongside English, identifying sterility status, intended use, and manufacturer information. The authority maintains post-market surveillance obligations, requiring licence holders to report device-related incidents and to withdraw or recall products found not to conform to the standards under which they were registered.

BD, Hologic, Inc., Devicor Medical Products, Inc., ARGON MEDICAL., SOMATEX Medical Technologies GmbH, INVIVO THERAPEUTICS, MDL SRL., STERYLAB S.r.l., UROMED Kurt Drews KG, BPB medica, Koninklijke Philips N.V., Medtronic, GENERAL ELECTRIC COMPANY, Leica Biosystems Nussloch GmbH, ZAMAR CARE., Stryker, Messe D&uuml, sseldorf GmbH, Kompass, COMPASS International Innovations, Inc., HAKKO CO. and LTD. and Cardinal Health are the suppliers covered in Saudi Arabia. Volume sits in Semi-automated core needle biopsy device at 50% of 2025 revenue; movement sits in Full-automated core needle biopsy device at 9.33% growth. The commercial size of that position is USD 38 million in 2025 and USD 77.3 million by 2034, 4% of the global total in the base year.

1% of global revenue is generated in South Africa; USD 9.5 million in 2025, reaching USD 19.3 million in 2034, and 25% of Middle East and Africa.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by type, application, clinical indication, imaging guidance, distribution channel, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.